For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial.
OBJECTIVES To determine the minimal time to successful intercourse after taking sildenafil citrate for erectile dysfunction ( ED ) . METHODS Male patients with ED ( mean age 60 years ; mean ED duration 7.0 years ) who were successfully treated with sildenafil ( 100 mg ) for 2 months or longer were r and omized to sildenafil ( n = 115 ) or placebo ( n = 113 ) for 4 weeks of double-blind treatment . Using a stopwatch , patients recorded the time needed to obtain an erection hard enough for sexual intercourse after taking the study drug at least 2 hours after eating . RESULTS Within 14 and 20 minutes of sildenafil dosing , 35 % and 51 % of sildenafil-treated patients , respectively , versus 22 % and 30 % of placebo-treated patients , respectively , had an erection that led to successful intercourse ( P < 0.05 for both ) . The median time to erection leading to successful intercourse after sildenafil dosing was 36 minutes compared with 141 minutes for placebo . CONCLUSIONS In this study , slightly more than one half of a population of prior sildenafil responders achieved an erection that led to successful sexual intercourse within 20 minutes of sildenafil administration , suggesting that the onset of action of sildenafil can be less than 30 minutes in men with ED
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .